Rationale: More information on risk factors for death from tuberculosis in the United States could help reduce the tuberculosis mortality rate, which has remained steady for more than a decade.
Americans still die of tuberculosis (TB), a preventable disease (1) . On the basis of death certificate data, the TB mortality rate in the United States was 0.2/100,000 population, or 555 deaths, in 2013 and has not changed since 2003 (2) . Despite the importance of TB mortality, limited information has been published about patients who die of TB and the frequency of potentially preventable deaths.
Many studies have documented the need for a systematic approach to measure TB-related deaths and determine the role that TB played in death. However, such studies often use death certificates as their main data source. Death certificates can misclassify the cause of death and underestimate the number who died with TB (3) (4) (5) (6) (7) . One study of death certificates found TB listed as an underlying or contributing cause of death in only 34% of persons who died with TB (4) . In a survey of resident physicians, only 33% who completed death certificates believed the death certificates were accurate; 20% who reported entering an incorrect cause of death stated they had done so because they were not familiar with the patient (5) . Although some studies have examined TB-related mortality beyond death certificates, many were limited by narrowly defined populations or small size (6, (8) (9) (10) (11) (12) .
Identifying risk factors for TB mortality could assist in the design of preventive interventions. Our primary objectives were to quantify and assess risk factors for TB-related deaths in the United States.
Methods
There were 1,304 adults with a verified diagnosis of TB (as reported to the Centers for Disease Control and Prevention [CDC] ) who died in the 15 study catchment areas in 2005 and 2006 (see Table E1 in the online supplement). All patients were included who were reported as dead at diagnosis or if the reason for treatment cessation was "died" on the Report of Verified Case of Tuberculosis form.
For all of the aforementioned study subjects, trained data abstractors from each study site reviewed inpatient and outpatient medical and laboratory records and immediate, underlying, and contributing causes of death from the death certificates and entered into the abstraction form for the patient.
All persons evaluating the TB relatedness of death took a 2-hour training where the TB-relatedness algorithm was reviewed and sample cases were discussed to ensure consistency of review. In addition, all persons performing TB-relatedness determinations referred to a TB-relatedness flowchart and procedural manual to ensure consistency of classification. Two study team members, at least one of whom was a clinician with TB expertise, reviewed each data abstraction form and independently classified each death as possibly or definitely TB related, unlikely or definitely not related, or unclassifiable, using an a priori algorithm ( Figure E1 ). Disagreements were resolved by a third independent reviewer. For the final analysis, definitely and possibly TB-related deaths were classified as TB-related deaths, and unlikely or definitely not TB-related deaths were classified as TBunrelated deaths. This classification is used for all analyses.
A Kaplan-Meier curve was created to compare the time to death for patients who died with a TB-related death and patients who died with a TB-unrelated death.
To study risk factors for TB-related death during therapy, persons who died before diagnosis or treatment initiation were excluded from the cases. Only adults were included because of the small number (n = 14) of pediatric (,18 yr) deaths. Control subjects were selected from the group of patients with verified TB reported in the catchment areas from 2005 to 2006, who had completed TB treatment (which may last up to 2 years after treatment initiation; approximately 18,000 patients). Control patients were frequency matched 1:1 to cases by catchment area and age category. As with cases, control medical records were abstracted in each study site by reviewing inpatient and outpatient medical and laboratory records. All available data for each control were entered into the data abstraction form.
All subjects were designated as having severe or extensive TB disease if they had acid-fast bacilli on smear microscopy (smear-positive disease), respiratory failure, bilateral pulmonary disease, extensive pulmonary destruction, pulmonary and extrapulmonary disease, or TB meningitis.
We analyzed categorical variables with the chi-square or Fisher exact test and continuous variables with the Wilcoxon rank sum test. We used the kappa coefficient to compare agreement on TB-related deaths between study algorithm and death certificate.
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causal pathway for TB-related death (13) . If covariates were correlated (phi value > 0.3), only the variable associated with the highest proportion of patients was included in the model. We excluded covariates that represented limited exposure opportunities for patients who died within the first month of treatment (health department monitoring, adverse reactions to TB therapy, treatment interruptions). Age, sex, meningeal TB status, and human immunodeficiency virus (HIV) status were included a priori in all models.
Covariates were added in descending order of bivariable odds ratios and were retained if their addition yielded a Wald chi-square P value < 0.05 and 1) changed the adjusted odds ratio associated with meningeal TB or HIV by at least 10% (14), or 2) improved the model fit as indicated by the likelihood ratio test. Interactions that were tested included HIV by meningeal TB, HIV by cognitive impairment, and HIV by sputum smear status, and absence of pyrazinamide in the initial treatment regimen by "liver condition" (defined as patient with cirrhosis or viral hepatitis or patient reported excess alcohol usage). Data were analyzed using SAS 9.3.
Institutional Review Boards at CDC and each study site approved the study. This study was funded by the Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, through a task order announced and managed by the Tuberculosis Epidemiologic Studies Consortium. (Figure 1 ). Figure 2 shows that those who had a TB-related death died sooner after their TB diagnosis than those who died of other causes.
Results
Almost all (98%) of the 942 adult patients with TB-related deaths had cultureconfirmed TB: 228 of 237 who died before TB treatment, and 692 of 705 who died during treatment. Of the 755 Mycobacterium tuberculosis isolates with drug susceptibility results, 58 (8%) were monoresistant (41 to isoniazid, 16 to pyrazinamide, and 1 to rifampin), 4 (0.5%) were resistant to more than one drug, and 14 (2%) displayed multidrug-resistant TB, defined as resistance to at least isoniazid and rifampin.
Among the 942 patients with TB-related deaths, 789 (84%) had at least one of the following: smear-positive disease (54%), bilateral pulmonary lesions (44%), extensive pulmonary destruction visible on chest image (31%), pulmonary and
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Could not be classified ORIGINAL RESEARCH extrapulmonary disease (23%), meningeal TB (10%), or miliary TB (7%). Concurrent medical conditions included chronic obstructive pulmonary disease (COPD) (25%), diabetes mellitus (25%), coronary artery disease (20%), viral hepatitis (12%), cancer (11%), and cirrhosis (10%) ( Table 1) .
(25%)
Of the 237 cases with TB-related deaths who died before starting treatment, 82% had pulmonary/pleural involvement; 10% had cavitary lesions on chest radiographs. Notably, 40% had an initial diagnosis other than TB, 56% had no TB nucleic acid amplification test performed, and 51% did not have a full TB diagnostic evaluation. Compared with those who died during treatment, cases who died before starting treatment were more likely to have extrapulmonary TB, unknown HIV status, a diagnosis or history of cancer, or no reported TB symptoms (Table 1) .
Adults with TB-related death within 30 days after starting TB treatment were older than those who died more than 30 days after starting TB treatment (Table E2) .
Death certificates were available for 1,093 of the 1,214 patients whose deaths could be classified as TB related or not using the study algorithm. We classified 847 deaths (77% of 1,093) as TB related and 246 (23%) as TB unrelated. Of the 847 algorithm-defined TB-related deaths, 469 (55%) had TB listed on the death certificate as the immediate, underlying, or contributing cause of death. Among adult patients with TB-related deaths, early death was more common if the death certificate did not mention TB. Almost two-thirds (66%) of those with no mention of TB on the death certificate died before treatment or within 30 days of treatment start, compared with 54% of those whose death certificates mentioned TB (P = 0.0001).
Compared with death determined to be related to TB by the study algorithm, the sensitivity of death certificate data (i.e., TB listed as underlying, immediate, or contributing cause of death) was 55% and specificity was 75%. Agreement between study algorithm and death certificate was modest (k = 0.21; 95% confidence interval [CI], 0.19-0.26) (Table E3 ).
In the case-control study, bivariable analysis showed that cases (adults with TB-related deaths who died during treatment) were more likely than control subjects (adults alive at least 2 years after treatment completion) to have severe or extensive disease: smear-positive disease (60% vs. 41%, P , 0.001), respiratory failure (50% vs. 3%, P , 0.001), bilateral disease (47% vs. 26%, P , 0.001), extensive pulmonary destruction (36% vs. 21%, P , 0.001), combined pulmonary and extrapulmonary disease (27% vs. 8%, P , 0.001), and meningeal disease (11% vs. 1%, P , 0.001).
Cases were also more likely to have been born in the United States (54% vs. 38%, P , 0.001), to have had an initial diagnosis other than TB (43% vs. 27% P , 0.001), to have refused treatment at any time during the treatment course (6% vs. 3%, P = 0.001), to have cognitive impairment (28% vs. 5% P , 0.001), to have had drug interactions with other medications (3% vs. 1%, P = 0.02), to report any TB symptom (93% vs. 85%, P , 0.001), and to report weight loss (65% vs. 56%, P = 0.001), fever (55% vs. 44%, P , 0.001), shortness of breath (49% vs. 29%, P , 0.001), or loss of appetite (40% vs. 25%, P , 0.001) ( Table 2) . Cases were more likely to be HIV-positive (20% vs. 5%, P , 0.001) or to have unknown HIV status (40% vs. 23%, P , 0.001). Cases were less likely to report cough (64% vs. 75%, P , 0.001), night sweats (27% vs. 33%, P = 0.01), or hemoptysis (11% vs. 16%, P = 0.003). There was no difference between the two groups in the proportion of patients with diabetes mellitus (DM) (26% vs. 23%, P = 0.11).
Bivariate analyses also showed differences in receipt of health services. Cases were more likely to have been diagnosed as inpatients (89% vs. 54%, P , 0.001) and to have received a portion of the intensive phase of TB treatment as inpatients (79% vs. 25%, P , 0.001). Cases were less likely to have had a health department home visit, to have been interviewed within a week of the health department's notification of their case, and to have had their home address recorded (11% vs. 1%, P , 0.001).
In multivariable analysis, factors associated with TB-related death while receiving TB treatment included receiving a portion of the intensive phase of therapy in the hospital (adjusted odds ratio [aOR], 6.5; 95% CI, 4.9-8.6), absence of pyrazinamide in the initial treatment regimen (aOR, 3.4; 95% CI, 1.9-6.0), cognitive impairment (aOR, 2.8; 95% CI, 1.9-4.2), receiving immunosuppressive medications such as prednisone or tumor necrosis factor-a inhibitors (aOR, 2.5; 95% CI, 1.1-5.6), COPD (aOR, 2.4; 95% CI, 1.7-3.3), bilateral pulmonary disease (aOR, 2.2; 95% CI, 1.6-2.9), no sputa collection for smear microscopy during pulmonary TB evaluation (aOR, 2.2; 95% CI, 1.5-3.3), liver conditions (aOR, 1.9; 95% CI, 1.4-2.7), cancer (aOR, 1.9; 95% CI, 1.9-5.4), and receiving a diagnosis other than TB before the TB diagnosis (aOR, 1.6; 95% CI, 1.2-2.2) ( Table 3 ). None of the interaction terms achieved statistical significance; therefore, they were not maintained in the final model.
Discussion
Tuberculosis, a treatable and preventable disease, contributed to death in almost ORIGINAL RESEARCH Almost three-fourths of persons with tuberculosis-related death died before diagnosis or within a month after treatment initiation. Many who died did not report tuberculosis symptoms, and few who died before treatment had cavities on chest radiograph, which may have obscured the diagnosis of tuberculosis, an infrequent disease in the United States. Our finding was consistent with other studies that found an association between atypical chest radiographic findings (i.e., noncavitary infiltrate) and death at diagnosis and before treatment (15, 16) . In our study, persons with tuberculosis-related deaths were more likely to have had an initial nontuberculosis diagnosis, such as pneumonia. This finding suggests patients may die or experience increased risk of death while providers pursue other diagnoses.
In a systematic review evaluating risk factors for tuberculosis death during treatment, Waitt and Squire hypothesized that studies demonstrating an association between increased comorbidities, social isolation, and death from tuberculosis may be a caused by delays in presenting to a provider with symptoms (17) . The role of cognitive impairment in death during tuberculosis treatment may be explained by patient delays in presenting to a provider (8, 17) , but could also be independently associated with mortality.
When compared with those dying before diagnosis, cases who died during treatment were more likely to be human immunodeficiency virus-positive, to have pulmonary and extrapulmonary disease, and to have extensive pulmonary destruction and bilateral disease on chest radiograph. Human immunodeficiency virus infection was an independent risk factor for tuberculosis-related death in our study and others (15, 16, 18, 19) . However, many decedents had unknown human immunodeficiency virus status, either because the test was not performed or the results were unknown. This finding underscores the importance of human immunodeficiency virus testing of all patients being evaluated for tuberculosis and extensive pulmonary and extrapulmonary conditions without a definitive diagnosis, because management of both tuberculosis and human immunodeficiency virus concurrently increases the likelihood of a successful outcome (20, 21) .
Findings of significant abnormalities on chest radiograph or combined pulmonary/extrapulmonary disease might increase the likelihood that the physician makes a tuberculosis diagnosis sooner. However, consistent with the extensive burden of disease, half the patients who died during treatment did so within a month of starting treatment.
Although previous studies identified diabetes mellitus as a risk factor for death in patients with tuberculosis (13, 22, 23) , our study found that diabetes did not contribute to tuberculosis-related death. The literature has been inconsistent about the role of diabetes in tuberculosis treatment outcomes (24, 25) .
Of note, 42 persons (6%) starting tuberculosis therapy had severe adverse reactions to antituberculosis medications, which may have exacerbated an underlying condition and led to death. In our study, the most common preexisting condition was liver disease. In a study evaluating mortality of patients with cirrhosis with and without tuberculosis, patients with cirrhosis were Patient pulmonary evaluation did not include collection of three consecutive sputum samples for AFB smear microscopy within 4 days of hospitalization, or within 30 days if the patient with pulmonary disease was diagnosed as an outpatient. For patients with extrapulmonary TB only, no imaging or laboratory tests were documented. found to have higher mortality 30 days to 1 year after starting treatment, suggesting that hepatotoxicity from tuberculosis treatment may be a source of higher mortality (26) . Careful monitoring of patients with cirrhosis early in their treatment could prevent mortality. Even after adjusting for age and factors that increased the risk of liver injury, we found that absence of pyrazinamide in the initial treatment regimen was associated with tuberculosis-related death. Clinicians might not prescribe pyrazinamide to patients with risks for liver injury because of its potential hepatotoxicity (27) . In fact, 24 of 59 (41%) patients who died during treatment without pyrazinamide had reported excess alcohol use or had viral hepatitis or cirrhosis, and only 3% had a pyrazinamide-resistant M. tuberculosis strain. Thus, the absence of pyrazinamide in the regimen may be partially explained by concerns about toxicity in patients with liver conditions, as drug resistance does not explain it. Further work is needed to understand the mechanism of pyrazinamide efficacy to develop drugs with a similar mechanism but without the toxicity.
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As seen in previous studies, our study confirmed that death certificates might incompletely capture tuberculosis disease when it is related to death. As slightly more than half of patients with a death certificate and tuberculosis-related death had tuberculosis listed as an immediate, underlying, or contributing cause of death (55%), the sensitivity of the death certificate to find a tuberculosis-related death was modest (55%). One explanation for the lower detection of tuberculosis-related deaths by the death certificate is that tuberculosis might be diagnosed many weeks after death, when the culture becomes positive and the death certificate has already been completed.
Several features of tuberculosis-related death stand out in this study. Decedents often did not have the classic symptoms (cough, hemoptysis, cavities on chest radiograph), which made an illness that is uncommon in the United States even easier to miss. Human immunodeficiency virus infection and liver conditions complicate tuberculosis and are also potential markers for increased mortality risk. The risk factors identified in this study may form the basis for the development of a tuberculosis mortality risk score, analogous to those that have been used to predict mortality in patients with tuberculosis in the hospital (28) and intensive care unit (29, 30) , which may help with earlier diagnosis, rapid treatment initiation, and enhanced care. A risk score for pulmonary tuberculosis using risk factors (similar to the ones we describe) that was developed using a derivation cohort and tested using a validation cohort was able to differentiate between low-, moderate-, and high-risk patients (31) . Bilateral disease on chest radiograph; extensive pulmonary destruction; immunosuppression; ORIGINAL RESEARCH meningeal, miliary, or peritoneal tuberculosis; cognitive impairment; and coexisting conditions of obstructive pulmonary disease, cancer, and underlying liver disease should be formally evaluated in scoring and predicting mortality. If scoring becomes routine, a high score could alert clinicians to patients who may benefit from more intensified management and monitoring. Even without a scoring system, when tuberculosis is diagnosed in a hospitalized patient, clinicians should recognize the increased risk of death.
Our study had limitations. We did not assess the impact of smoking on tuberculosisrelated death and could not fully assess the impact of health department monitoring, because a large proportion of patients died before there was an opportunity for such intervention. Because few hospital records noted the provision of directly observed therapy, its potential protective role could not be evaluated. Similarly, we could not evaluate the association between provider type and patient outcome, because patients who died were overwhelmingly cared for in the hospital, with multiple providers during at least some portion of their diagnosis and treatment. Our analysis also assumes that our algorithm for tuberculosis-related death was more accurate than the death certificate. Given that our classification was based on data from an extensive chart review of medical and public health records and multiple independent reviewers, we feel confident that any residual bias is smaller than what might have occurred had the study been conducted with death certificates only in the classification. Because the study design required extensive medical record review, we were unable to assess risk factors for tuberculosis-related death before presentation to a healthcare provider. Finally, these data were collected on cases reported in 2005 to 2006; because of the extensive nature of the study organization and chart review required, more recent data are not available.
Our study underscores the importance of preventing tuberculosis deaths by preventing tuberculosis disease in the first place. In low-incidence nations with current diagnostic tools, tuberculosis diagnosis is often missed or delayed, and tuberculosis deaths most often occur within weeks of diagnosis. Current tuberculosis treatment regimens are not always sufficient to reverse extensive disease. Finally, many patients who successfully complete antituberculosis treatment often live less robust and shorter lives (32) (33) (34) .
Fortunately, the public health and medical community have tools (more specific tests in the form of interferon-g release assays and shorter treatment regimens that are more likely to be completed) to identify and treat latent tuberculosis infection (35) (36) (37) . Increased testing and treatment for latent tuberculosis infection can reduce the number of persons who develop and die of this preventable disease. n A diagnosis other than TB was made before TB diagnosis. **Patient pulmonary evaluation did not include collection of three consecutive sputum samples for acidfast bacilli smear microscopy within 4 days of hospitalization, or within 30 days if the patient with pulmonary disease was diagnosed as an outpatient. For patients with extrapulmonary TB only, no imaging or laboratory tests were documented.
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